top of page
Life-Cycle Insights Logo

DRUG LIFE-CYCLE INSIGHTS ACROSS THE GLOBE

Pharmaceuticals  |  Biotech  |  Biosimilars

IPD's Life-Cycle Insights subscription provides unmatched visibility into the life cycle of drugs and biologics, from early-stage pipeline assets to mature, established products. 

  • Brand, generic, and biosimilar launch tracking

  • Loss-of-exclusivity insight, timing, and analytics

  • Innovative drug pipeline tracking

  • Litigation analysis and forecasted litigation outcomes

  • Regulatory impacts

Our team of former patent litigators, former Federal Circuit Clerks, PhD scientists, and patent researchers analyze public and proprietary data to provide summarized, comprehensive, strategic, and tactical analysis and insights. 

Our subscribers gain around-the-clock access to IPD's proprietary web-based platform with real-time email alerts and expert consultations.

  • Data and analysis covering thousands of drugs and biologics in all major disease states and indications

  • Brand, generic, and biosimilar launch tracking tools to monitor new market entrants to the market and their impact on product pricing

  • Loss-of-exclusivity forecasts, patent information, regulatory data, generic-filer information, API complexity information, disease-area overviews, competitive intelligence, and drug pipelines up to
    10 years in the future

  • Information on pending litigation and regulatory proceedings such as court cases, hearings, and oppositions that affect launch timing, direct vs. indirect competitors, and marketplace shifts

Explore Recent Reports

June 2019

Losing by Winning at the Patent Office: Zytiga Case Illustrates How IPR Estoppel Could Reshape Patent Challenges and Delay Generic Launches

What does a recent case decided by the Federal Circuit Court mean for brand and generic manufacturer strategy in the future? Our Insight Brief reveals a subplot with potentially high stakes for payers, providers, and patients alike...

February 2020

Authorized to Compete: Shifting Competitive Strategies Require a Fresh Look at Authorized Generics

Authorized generic (AG) drugs have existed for more than 40 years and have long been utilized as a life-cycle management strategy by manufacturers to compete with generics...

November 2019

There’s Nothing Generic About a Generic Launch: How Shifting Market Dynamics and Stakeholder Strategies Are Disrupting Standard Assumptions for Forecasting the Impact of Generic Entrants

Over the past several years, the pharmaceutical industry has shifted away from traditional small-molecule drugs to focus more on complex formulations and specialty agents. The additional market complexities that are accompanying this shift have impacted stakeholder strategies for all drugs facing loss of exclusivity...

September 2021

Recent Trends in ANDA Submissions One Year Prior to NCE Exclusivity Expirations

In this report, IPD explores recent trends in ANDA submissions one year prior to the expiration of New Chemical Entity (“NCE”) exclusivity associated with a referenced branded drug, referred to as the “NCE-1 date...”

bottom of page